Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage
Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD - read this article along with other careers information, tips and advice on BioSpace
A personalized intervention that focused on known Alzheimer s risk factors showed "modest" improvement at 2 years that was greater than a control intervention, new results from the SMAART study show.
"This is exactly what we need: a well-done trial with a control group to show that it actually works," said one expert, cautioning that it provides only proof of concept.
Use of a combination product containing quarter doses of four different drugs reduced blood pressure by almost 5 mm Hg more than a standard dose of one antihypertensive agent.